Medtech company to invest €200m in R&D at Cork facilities
Medtech company Stryker is investing over €200m in research, development and innovation projects across three of its five Cork facilities.
The investment is part of the company’s drive to continue innovation in delivering products and services across its medical surgical, orthopaedics and neurotechnology and spine offerings.
The €200m R&D progamme, which is supported by the Government through IDA Ireland, includes investments in projects at its AMagine Institute, which develops additive manufacturing products for three divisions, spine, craniomaxillofacial and joint replacement.
In addition, investment by the US-headquartered company will go into its neurovascular business, which develops stroke treatment products, and its Instruments Innovation Centre.
The centre designs, develops and commercialises new surgical devices across a range of surgical procedures.
Spencer Stiles, group president, Instruments, Neurotechnology & Spine at Stryker, said: "At Stryker we are committed to making healthcare better for our customers and their patients."
"The continued growth and investment in Ireland is the result of many factors, inclusive of the research, development and innovation support from IDA Ireland and the partnerships built with leading Irish universities and research centers."
Last year, Stryker invested more than 6pc of its global sales into research and development.
The news was welcomed by both Minister for Business, Enterprise & Innovation, Heather Humphreys and IDA Ireland.